{"id":"formestane","rwe":[{"pmid":"38605570","year":"2025","title":"Development of 3β,4α-dihydroxy-5α-androstan-17-one standard solution for doping analyses.","finding":"","journal":"Drug testing and analysis","studyType":"Clinical Study"},{"pmid":"38369486","year":"2024","title":"Adrenarche-accompanied rise of adrenal sex steroid precursors prevents NAFLD in Young Female rats by converting into active androgens and inactivating hepatic Srebf1 signaling.","finding":"","journal":"BMC genomics","studyType":"Clinical Study"},{"pmid":"37820497","year":"2024","title":"Sphingosine-1-phosphate mediates FSH-induced cell viability but not steroidogenesis in bovine granulosa cells.","finding":"","journal":"Theriogenology","studyType":"Clinical Study"},{"pmid":"37406756","year":"2023","title":"Dermal repeated dose toxicity study of the anti-breast cancer drug Formestane cream in Bama minipig.","finding":"","journal":"Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association","studyType":"Clinical Study"},{"pmid":"37056757","year":"2023","title":"The transdermal cream of Formestane anti-breast cancer by controlling PI3K-Akt pathway and the tumor immune microenvironment.","finding":"","journal":"Frontiers in immunology","studyType":"Clinical Study"}],"tags":[{"label":"formestane","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Aromatase","category":"target"},{"label":"CYP19A1","category":"gene"},{"label":"L02BG02","category":"atc"},{"label":"Active","category":"status"},{"label":"Carcinoma of female breast","category":"indication"},{"label":"Antineoplastic Agents","category":"pharmacology"},{"label":"Aromatase Inhibitors","category":"pharmacology"},{"label":"Enzyme Inhibitors","category":"pharmacology"},{"label":"Estrogen Antagonists","category":"pharmacology"},{"label":"Hormone Antagonists","category":"pharmacology"},{"label":"Steroid Synthesis Inhibitors","category":"pharmacology"}],"phase":"marketed","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=FORMESTANE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T01:17:26.990426+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T01:17:43.184901+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T01:17:33.328399+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=FORMESTANE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T01:17:33.689613+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL132530/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T01:17:34.476677+00:00"}},"allNames":"lentaron","offLabel":[],"synonyms":["formestane","lentaron"],"timeline":[{"date":"1993-01-01","type":"positive","source":"DrugCentral","milestone":"YEAR INTRODUCED approval"}],"aiSummary":"Formestane (Lentaron) is an aromatase inhibitor marketed for the treatment of carcinoma of the female breast, competing in a class with several off-patent generics including anastrozole, letrozole, and exemestane. Its key strength lies in its mechanism of action, which effectively blocks the aromatase enzyme to reduce estrogen production, a critical factor in breast cancer management. The primary risk is the strong competition from multiple generic alternatives, which may limit Formestane's market share and revenue potential, especially as its key composition patent expires in 2028.","approvals":[{"date":"1993-01-01","orphan":false,"company":"","regulator":"YEAR INTRODUCED"}],"brandName":"Lentaron","ecosystem":[{"indication":"Carcinoma of female breast","otherDrugs":[{"name":"doxorubicin","slug":"doxorubicin","company":""},{"name":"methotrexate","slug":"methotrexate","company":"Dava Pharms Inc"},{"name":"tamoxifen","slug":"tamoxifen","company":""},{"name":"testolactone","slug":"testolactone","company":""}],"globalPrevalence":null}],"mechanism":{"target":"Aromatase","targets":[{"gene":"CYP19A1","source":"DrugCentral","target":"Aromatase","protein":"Aromatase"}],"modality":"Small Molecule","drugClass":"formestane","explanation":"","oneSentence":"","technicalDetail":"Formestane (17-(1-methylethyl)-17-hydroxy-1,4-androstadien-3-one) is a non-steroidal, irreversible inhibitor of the aromatase enzyme (CYP19), which is responsible for the biosynthesis of estrogens from androgens."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1238","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=FORMESTANE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T11:38:07.463127","_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T01:17:43.185021+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"aminoglutethimide","drugSlug":"aminoglutethimide","fdaApproval":"1980-10-29","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"anastrozole","drugSlug":"anastrozole","fdaApproval":"1995-12-27","genericCount":19,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"letrozole","drugSlug":"letrozole","fdaApproval":"1997-07-25","genericCount":19,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"exemestane","drugSlug":"exemestane","fdaApproval":"1999-10-21","genericCount":11,"patentStatus":"Off-patent — generic available","relationship":"same-class"}],"genericName":"formestane","indications":{"approved":[{"name":"Carcinoma of female breast","source":"DrugCentral","snomedId":447782002,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"aminoglutethimide","brandName":"aminoglutethimide","genericName":"aminoglutethimide","approvalYear":"1980","relationship":"same-class"},{"drugId":"anastrozole","brandName":"anastrozole","genericName":"anastrozole","approvalYear":"1995","relationship":"same-class"},{"drugId":"letrozole","brandName":"letrozole","genericName":"letrozole","approvalYear":"1997","relationship":"same-class"},{"drugId":"exemestane","brandName":"exemestane","genericName":"exemestane","approvalYear":"1999","relationship":"same-class"}],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NDDF":"005805","UNII":"PUB9T8T355","CHEBI":"CHEBI:75172","INN_ID":"6877","RXNORM":"15070","UMLSCUI":"C0048306","chemblId":"CHEMBL132530","ChEMBL_ID":"CHEMBL132530","KEGG_DRUG":"D07260","DRUGBANK_ID":"DB08905","PUBCHEM_CID":"11273","SNOMEDCT_US":"327363004","MESH_SUPPLEMENTAL_RECORD_UI":"C014594"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":174,"therapeuticAreas":["Oncology"],"atcClassification":{"source":"DrugCentral","atcCode":"L02BG02","allCodes":["L02BG02"]},"biosimilarFilings":[],"recentPublications":[{"date":"2025 Feb","pmid":"38605570","title":"Development of 3β,4α-dihydroxy-5α-androstan-17-one standard solution for doping analyses.","journal":"Drug testing and analysis"},{"date":"2024 Feb 19","pmid":"38369486","title":"Adrenarche-accompanied rise of adrenal sex steroid precursors prevents NAFLD in Young Female rats by converting into active androgens and inactivating hepatic Srebf1 signaling.","journal":"BMC genomics"},{"date":"2024 Jan 1","pmid":"37820497","title":"Sphingosine-1-phosphate mediates FSH-induced cell viability but not steroidogenesis in bovine granulosa cells.","journal":"Theriogenology"},{"date":"2023 Aug","pmid":"37406756","title":"Dermal repeated dose toxicity study of the anti-breast cancer drug Formestane cream in Bama minipig.","journal":"Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association"},{"date":"2023","pmid":"37056757","title":"The transdermal cream of Formestane anti-breast cancer by controlling PI3K-Akt pathway and the tumor immune microenvironment.","journal":"Frontiers in immunology"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"OTHER","regulator":"YEAR INTRODUCED","status":"approved","approval_date":"1993-01-01T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T01:17:43.185021+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"enriching","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":false,"score":1}}